BRD4 and osteosarcoma: In osteosarcoma preclinical models, PROTACs that target BET family proteins, specifically BRD4, 3 and 2 synergise with chemotherapy, trigger apoptosis, cell cycle arrest and significantly reduce tumour volume [218, 219].